REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrino...
| Symbol | ADAUSD |
| Exchange | CCC |
| ICO Date | 01.10.2017 |
| Circulating Supply | 36B |
| Total Supply | 45B |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrino...
Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript
PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies ...
DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and ...
SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial...
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sess...
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, includi...
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ...
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at ADA
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 01.11.2026 | $0.192850 | $0.194570 | $0.192480 | $0.193390 | 160M | +0.28% |
| 31.10.2026 | $0.194850 | $0.196550 | $0.191670 | $0.192640 | 130M | -1.13% |
| 30.10.2026 | $0.189980 | $0.195300 | $0.181890 | $0.194880 | 370M | +2.58% |
| 29.10.2026 | $0.205820 | $0.208460 | $0.187200 | $0.189970 | 580M | -7.70% |
| 28.10.2026 | $0.205630 | $0.209770 | $0.200440 | $0.205780 | 340M | +0.07% |
| 27.10.2026 | $0.206330 | $0.206930 | $0.200840 | $0.205690 | 190M | -0.31% |
| 26.10.2026 | $0.203960 | $0.207850 | $0.200200 | $0.206390 | 240M | +1.19% |
| 25.10.2026 | $0.207690 | $0.209140 | $0.201680 | $0.203750 | 190M | -1.90% |
| 24.10.2026 | $0.210520 | $0.212190 | $0.200280 | $0.207720 | 270M | -1.33% |
| 23.10.2026 | $0.211900 | $0.218480 | $0.206060 | $0.210630 | 260M | -0.60% |
| 22.10.2026 | $0.225120 | $0.226720 | $0.209500 | $0.211950 | 340M | -5.85% |
| 21.10.2026 | $0.223680 | $0.230390 | $0.221730 | $0.224970 | 310M | +0.58% |
| 20.10.2026 | $0.217910 | $0.226460 | $0.214440 | $0.223670 | 280M | +2.64% |
| 19.10.2026 | $0.220960 | $0.222710 | $0.215100 | $0.217900 | 220M | -1.38% |
| 18.10.2026 | $0.219230 | $0.221730 | $0.210790 | $0.220980 | 250M | +0.80% |
| 17.10.2026 | $0.225330 | $0.225430 | $0.213650 | $0.219240 | 220M | -2.70% |
| 16.10.2026 | $0.229660 | $0.233250 | $0.221020 | $0.225370 | 300M | -1.87% |
| 15.10.2026 | $0.230060 | $0.232000 | $0.215730 | $0.229700 | 540M | -0.16% |
| 14.10.2026 | $0.235660 | $0.238850 | $0.226390 | $0.229910 | 460M | -2.44% |
| 13.10.2026 | $0.232680 | $0.240250 | $0.224040 | $0.235710 | 480M | +1.30% |
| 12.10.2026 | $0.251940 | $0.255800 | $0.232540 | $0.232640 | 560M | -7.66% |
| 11.10.2026 | $0.248980 | $0.256180 | $0.244880 | $0.251960 | 400M | +1.20% |
| 10.10.2026 | $0.242980 | $0.259210 | $0.242210 | $0.248970 | 560M | +2.47% |
| 09.10.2026 | $0.232170 | $0.243450 | $0.231240 | $0.242870 | 570M | +4.61% |
| 08.10.2026 | $0.255310 | $0.258080 | $0.223620 | $0.232190 | 920M | -9.06% |
| 07.10.2026 | $0.267380 | $0.267670 | $0.247350 | $0.255520 | 750M | -4.44% |
| 06.10.2026 | $0.270410 | $0.282210 | $0.265500 | $0.267350 | 940M | -1.13% |
| 05.10.2026 | $0.259700 | $0.276710 | $0.257730 | $0.270380 | 1.2B | +4.11% |
| 04.10.2026 | $0.243870 | $0.268530 | $0.242180 | $0.259700 | 890M | +6.49% |
| 03.10.2026 | $0.244500 | $0.248630 | $0.242690 | $0.243900 | 260M | -0.25% |